Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

4 years ago
In Focus
Marketing

Not cheap­er by the dozen: Bris­tol My­ers be­comes the 12th phar­ma com­pa­ny to re­strict 340B sales

4 years ago
Pharma

New J&J CEO Joaquin Du­a­to promis­es an ag­gres­sive M&A hunt in quest to grow phar­ma sales

4 years ago
Pharma

Mar­ket­ingRx roundup: Pfiz­er de­buts Pre­vnar 20 TV ads; Lil­ly gets first FDA 2022 pro­mo slap down let­ter

4 years ago
Pharma
Marketing

Phar­ma reps need to bone up on sci­en­tif­ic da­ta and re­al-world ev­i­dence for on­col­o­gy dis­cus­sions: study

4 years ago
Pharma
Marketing

Am­gen’s #Dear­Asth­ma spon­sored tweet lands big on game day, spark­ing thou­sands to re­spond

4 years ago
Pharma
Marketing

Pfiz­er, Bris­tol My­ers dom­i­nate top 10 pre­dic­tions for the best-sell­ing drugs of 2022

4 years ago
Pharma

CBO re­port high­lights ris­ing cost of brand-name drugs in Medicare as Con­gress con­sid­ers price ne­go­ti­a­tions

4 years ago
Pharma

FDA slams door to piv­otal tri­al for bub­ble boy dis­ease gene ther­a­py as Mus­tang Bio runs in­to an­oth­er hold

4 years ago
Cell/Gene Tx

Covid-19 roundup: Pfiz­er/BioN­Tech launch Omi­cron-spe­cif­ic vac­cine tri­al; UK to re­cruit thou­sands more for ...

4 years ago
Coronavirus

Capri­cor gets up to $735M for Duchenne drug's US rights; PCI Biotech ends bile duct can­cer clin­i­cal tri­al

4 years ago
News Briefing

As push to dis­rupt PD-(L)1 pric­ing heats up, Check­point trum­pets a piv­otal suc­cess

4 years ago
R&D

FDA slams Eli Lil­ly's 'mis­lead­ing' In­sta­gram ad for its type 2 di­a­betes in­jec­tion

4 years ago
FDA+

Backed by Bay­er's Leaps, Boston-based Celli­no lands $80M for cell ther­a­py-in-box

4 years ago
Financing
Startups

Gen 2: Berke­ley spin­out lands $175M megaround to keep it on the cut­ting edge of the boom­ing gene-edit­ing field

4 years ago
Financing

Sur­prise piv­ot rocks eF­FEC­TOR's I/O plans — al­though ex­ecs promise big­ger slice of the NSCLC mar­ket in the long run

4 years ago
R&D

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

4 years ago
R&D
In Focus

Nasal sprays to stave off virus­es days at a time? J&J’s newest biotech part­ner draws $140M for 'proac­tive' ap­proach

4 years ago
Financing

Claim­ing a win where Gilead failed, Sier­ra touts PhI­II suc­cess in a JAK in­hibitor — and is ready to take it to the ...

4 years ago
R&D

US re­stricts use of two mon­o­clon­al an­ti­bod­ies that don't work against Omi­cron

4 years ago
FDA+
Coronavirus

How much? Pfiz­er leads top phar­ma com­pa­nies' ramped up lob­by spend­ing on Con­gress

4 years ago
Pharma

GSK looks to stand out in the se­vere asth­ma space with at-home in­jec­tions for kids 6 to 11 years old

4 years ago
Pharma

BeiGene/No­var­tis tout new PD-1 da­ta; No­var­tis plans down­siz­ing in Tokyo

4 years ago
News Briefing

Eli Cas­din co-leads $250M in­fu­sion in­to mi­croflu­idics play­er that land­ed NIH fund­ing for Covid-19 test­ing

4 years ago
Financing
Deals
First page Previous page 594595596597598599600 Next page Last page
A service from the Financial Times